MY180581A - A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof - Google Patents
A crystalline form of cyclosporine a, methods of preparation, and methods for use thereofInfo
- Publication number
- MY180581A MY180581A MYPI2013004226A MYPI2013004226A MY180581A MY 180581 A MY180581 A MY 180581A MY PI2013004226 A MYPI2013004226 A MY PI2013004226A MY PI2013004226 A MYPI2013004226 A MY PI2013004226A MY 180581 A MY180581 A MY 180581A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- cyclosporine
- preparation
- crystalline form
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490887P | 2011-05-27 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY180581A true MY180581A (en) | 2020-12-02 |
Family
ID=46178866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013004226A MY180581A (en) | 2011-05-27 | 2012-05-25 | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof |
Country Status (19)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2779994T3 (da) * | 2011-11-15 | 2020-05-18 | Allergan Inc | Suspensioner af cyclosporin a form 2 |
| AU2012339695B2 (en) * | 2011-11-15 | 2017-10-05 | Allergan, Inc. | Sustained action formulation of cyclosporin Form 2 |
| RU2635547C2 (ru) | 2011-11-15 | 2017-11-14 | Аллерган, Инк. | Форма 2 циклоспорина а и способ ее получения |
| WO2013074616A1 (en) * | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Autoclavable suspensions of cyclosporin a form 2 |
| CN104487449A (zh) | 2012-06-01 | 2015-04-01 | 阿勒根公司 | 环孢菌素a类似物 |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| US10524661B2 (en) * | 2013-06-12 | 2020-01-07 | Proactive Live, Inc. | Sleep monitoring and stimulation |
| AU2015289387B2 (en) | 2014-07-18 | 2020-10-22 | Allergan, Inc. | Suspension compositions of cyclosporin A for subconjunctival and periocular injection |
| WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
| US10443292B2 (en) * | 2016-04-25 | 2019-10-15 | Magna Closures, Inc. | Non-contact obstacle detection system for motor vehicles |
| RU2766160C2 (ru) | 2017-05-17 | 2022-02-08 | Юю Фарма, Инк. | Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента |
| US11613558B2 (en) | 2018-11-14 | 2023-03-28 | Yuyu Pharma, Inc. | Peptides and pharmaceutical compositions for treating eye diseases |
| KR20250088544A (ko) | 2022-10-20 | 2025-06-17 | 추가이 세이야쿠 가부시키가이샤 | 고리형 펩티드 결정을 제조하는 방법 |
| JPWO2024195801A1 (cg-RX-API-DMAC7.html) | 2023-03-20 | 2024-09-26 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU203564B (en) * | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
| GB9105705D0 (en) * | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| US6254860B1 (en) | 1999-04-13 | 2001-07-03 | Allergan Sales, Inc. | Ocular treatment using cyclosporin-A derivatives |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| CN101687013A (zh) * | 2007-05-04 | 2010-03-31 | 阿勒根公司 | 环孢菌素在治疗具有人工晶状体的患者中的用途 |
| BRPI0822221A2 (pt) * | 2008-01-04 | 2015-06-23 | Alcon Pharmaceuticals Ltd | Composições aquosas e estáveis de ciclosporina |
-
2012
- 2012-05-25 WO PCT/US2012/039611 patent/WO2012166610A1/en not_active Ceased
- 2012-05-25 AU AU2012262513A patent/AU2012262513B2/en not_active Ceased
- 2012-05-25 EP EP18211911.5A patent/EP3521302A1/en not_active Withdrawn
- 2012-05-25 UA UAA201314231A patent/UA113627C2/uk unknown
- 2012-05-25 RU RU2013155033/04A patent/RU2602062C2/ru active
- 2012-05-25 CA CA2836946A patent/CA2836946C/en active Active
- 2012-05-25 CN CN201280033382.7A patent/CN103649108B/zh active Active
- 2012-05-25 BR BR112013030554-1A patent/BR112013030554B1/pt active IP Right Grant
- 2012-05-25 MY MYPI2013004226A patent/MY180581A/en unknown
- 2012-05-25 SG SG10201607344UA patent/SG10201607344UA/en unknown
- 2012-05-25 KR KR1020137034444A patent/KR102079402B1/ko not_active Expired - Fee Related
- 2012-05-25 US US13/480,710 patent/US8772245B2/en active Active
- 2012-05-25 EP EP12724525.6A patent/EP2714720B1/en active Active
- 2012-05-25 MX MX2013013855A patent/MX362271B/es active IP Right Grant
- 2012-05-25 JP JP2014512145A patent/JP6163482B2/ja active Active
- 2012-05-28 TW TW101119051A patent/TWI554522B/zh not_active IP Right Cessation
- 2012-05-28 AR ARP120101878A patent/AR086586A1/es not_active Application Discontinuation
-
2013
- 2013-11-17 IL IL229475A patent/IL229475A0/en unknown
- 2013-11-19 ZA ZA2013/08665A patent/ZA201308665B/en unknown
- 2013-11-26 CL CL2013003400A patent/CL2013003400A1/es unknown
-
2014
- 2014-07-02 US US14/322,475 patent/US9206228B2/en active Active
-
2015
- 2015-12-07 US US14/961,132 patent/US20160083432A1/en not_active Abandoned
-
2016
- 2016-06-15 AU AU2016203990A patent/AU2016203990A1/en not_active Abandoned
-
2017
- 2017-11-21 AU AU2017265008A patent/AU2017265008A1/en not_active Abandoned
-
2019
- 2019-06-14 AU AU2019204192A patent/AU2019204192B2/en not_active Ceased
-
2021
- 2021-01-13 US US17/148,315 patent/US20210269484A1/en not_active Abandoned
-
2022
- 2022-01-27 IL IL290158A patent/IL290158A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY180581A (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| SG10201906113RA (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| EA033455B1 (ru) | Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе | |
| GEP201706695B (en) | Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases | |
| CA2865011C (en) | Methods and compositions for treating huntington's disease | |
| NZ708501A (en) | Treatment of pulmonary disease | |
| MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. | |
| TN2013000485A1 (en) | 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group | |
| WO2013177133A3 (en) | Generation of human ips cells by a synthetic self- replicative rna | |
| PH12014500904B1 (en) | Antibody formulations and methods | |
| PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| SG10202010665YA (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders | |
| WO2012106393A3 (en) | Withanolide isolated from physalis longifolia and analogs and methods of use thereof | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX370253B (es) | Composiciones de compuestos de jasmonato y métodos de uso de las mismas. | |
| UA108878C2 (ru) | Ингибиторы протеинтирозинкиназной активности | |
| WO2012065110A3 (en) | S-protected cysteine analogs and related compounds | |
| MX2013012233A (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas. | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MY166314A (en) | Alpha1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations | |
| AU2012339701A8 (en) | Autoclavable suspensions of cyclosporin A Form 2 |